Ya-Han Wang

Dr. Ya-Han Wang

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2024 in Brain and Behavior
Verified
Journal Article
Open access
KZKai‐Xin Zhang
Kai‐Xin Zhang
NSNing Sheng
Ning Sheng
PDPeng‐Li Ding
Peng‐Li Ding
JZJi‐Wei Zhang
Ji‐Wei Zhang
XXXiang-Qing Xu
Xiang-Qing Xu
YWYa-Han Wang
Ya-Han Wang
Introduction: Alzheimer's disease (AD) is a neurodegenerative disease characterized by Amyloid plaques and neurofibrillary tangles. We explored the potential mechanism by which Danggui Shaoyao San (DSS) modulates central glucose metabolism via the insulin receptor substrate 1 (IRS1)/glycogen synthase kinase‐3β (GSK3β)/Wnt3a‐β‐catenin pathway, thereby exerting protective effects on cognitive functions.Methods: In vitro, HT22 cells were induced with streptozotocin (STZ) to investigate the impact of GSK3β on pathway transduction. The active components in the DSS stock solution were validated using mass spectrometry. Subsequently, an AD model in C57BL/6J mice was established through STZ injection into both ventricles. The success of the model was validated behaviorally and pathologically. The Morris Water Maze (MWM) test, immunohistochemistry, Western blotting, quantitative reverse transcription‐PCR, and 18F‐fluorodeoxyglucose‐positron emission tomography (FDG‐PET) were employed to evaluate the influence of DSS on memory and pathological changes in AD.Results: The DSS stock solution, rich in active components, ameliorated the memory deficits in AD mice in the MWM. In vitro, GSK3β exhibited regulatory control over Wnt and β‐catenin, with GSK3β inhibition mitigating β‐amyloid and tau redundancies at protein and gene levels, facilitating signal transduction. In vivo, DSS impacted key targets in the IRS1/GSK3β/Wnt3a‐β‐catenin pathway, mitigated senile plaques resulting from amyloid β (Aβ) deposition and neurofiber tangles induced by tau hyperphosphorylation, and alleviated the decline in central glucose metabolism observed in FDG‐PET.Conclusions: Our findings suggest that DSS potentially confers cognitive protection by alleviating central hypoglycemia through the IRS1/GSK3β/Wnt3a‐β‐catenin pathway. This may serve as a promising therapeutic avenue for AD.

1 February 2025 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
KZKai-Xin Zhang
Kai-Xin Zhang
JZJi-Wei Zhang
Ji-Wei Zhang
YJYan-Hong Jiang
Yan-Hong Jiang
YWYi-Ran Wang
Yi-Ran Wang
ZLZhen-Ling Liu
Zhen-Ling Liu
YWYa-Han Wang
Ya-Han Wang
Background: Danggui-Shaoyao-San (DSS) is a traditional Chinese medicine prescription with a history of nearly 2000 years, originally widely used for gynecological diseases, and in recent years research has found that DSS also has a good therapeutic effect on Alzheimer’s disease (AD). Purpose: The objective is to investigate the metabolic components of the DSS in the blood and the potential mechanisms for AD. Materials and Methods: Liquid chromatography‒mass spectrometry (LC-MS) combined with gas chromatography‒mass spectrometry (GC-MS) based non-targeted metabolomics were used to conduct in-depth research. Serum Pharmacology was used to analyze potential mechanisms of DSS for AD. C57BL/6J mice and Hippocampal neuronal cell line (HT-22) were used to prepare the AD model. Enzyme linked immunosorbent assay (Elisa), quantitative polymerase chain reaction (q-PCR), Morris water maze,Western blot (WB), Immunohistochemical and Immunofluorescence were used to study the effect of DSS on AD. Flow cytometry and Cell Counting Kit-8 (CCK-8) reveal the effect of DSS serum on HT-22 proliferation and apoptosis. Results: A total of 57 metabolic components were screened in DSS serum. Serum Pharmacology revealed that the calcium signaling pathway and cAMP/PKA/CREB pathway may be a potential mechanism through which DSS treated AD. DSS can reduce aberrant phosphorylation of Tau and modulates cAMP/PKA/CREB pathway to improve cognition and apoptosis in AD mice. DSS serum can increase the cell viability of HT-22 and reduce apoptosis mainly by alleviating mitochondrial calcium overloading. Conclusion: DSS can modulate the calcium signaling pathway and enhance the cAMP/PKA/CREB signaling pathway to ameliorate Tau aberrant phosphorylation, cognitive deficits and neuronal apoptosis after AD.

1 January 2025 in Mediators of Inflammation
Verified
Journal Article
Open access
PDPeng-Li Ding
Peng-Li Ding
KZKai-Xin Zhang
Kai-Xin Zhang
FYFang Yao
Fang Yao
WCWen-Qiang Cui
Wen-Qiang Cui
ZLZhen-Ling Liu
Zhen-Ling Liu
XXXiang-Qing Xu
Xiang-Qing Xu
Background: The pathophysiological progression during the hyperacute phase of acute ischemic stroke (AIS) critically determines clinical outcomes. Identification of phase‐specific biomarkers and elucidation of their temporal regulatory mechanisms are pivotal for optimizing therapeutic interventions. Methods: Disease signature genes and their mechanisms of action were screened based on the Gene Expression Omnibus database. This involved the use of differentially expressed gene screening, weighted gene co‐expression network analysis, Mfuzz analysis, Gene Ontology, Kyoto Encyclopedia of Genes and Genomes enrichment analysis, support vector machines, random forest algorithms, and gene set enrichment analysis. The expression of disease‐characteristic genes and their related mechanisms were further validated in both in vivo and in vitro models. Results: Six hyperacute‐phase signature genes ( Pip5k1c , Nlgn2 , Fzd2 , Cd86 , Agpat1 , and Degs2 ) were identified in the hyperacute phase of AIS. In light of the gene effect mechanism, the regulation of the neuroinflammatory response and apoptosis by the TLR2/TLR4/NF‐ κ B pathway was monitored in the hyperacute phase of AIS at three times: 3, 6, and 12 h. The results indicated a progressively intensified neuroinflammatory response and the fluctuating growth of early apoptosis changes. Conclusion: This study systematically identifies hyperacute‐phase‐specific biomarkers in AIS and delineates their temporal regulatory logic. The time‐course dynamics of neuronal apoptosis and inflammatory regulation in the hyperacute phase of AIS were monitored. The observed biphasic apoptotic pattern provides mechanistic insights for developing chronologically targeted therapies, such as timed inhibition of TLR4/CD86 during 0–3 h to block inflammatory initiation, or administration of Agpat1 agonists at 3–6 h to stabilize mitochondrial function. These findings help alleviate the current ‘molecular blind spot’ in early stroke diagnosis and intervention.

19 September 2025 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
WLWei Liu
Wei Liu
YZYanan Zhao
Yanan Zhao
TLTingting Liu
Tingting Liu
YWYilei Wang
Yilei Wang
DYDongli Yin
Dongli Yin
YWYa-Han Wang
Ya-Han Wang
Background: Kaixin San Jiawei Granule (KSG) is a traditional Chinese medicine formulation derived from classical prescriptions. Although it has shown promise in treating Alzheimer’s disease (AD), its precise mechanisms of action remain unclear. This study aimed to systematically investigate the molecular mechanisms underlying KSG’s therapeutic effects on AD through an integrative approach combining network pharmacology with experimental validation.Methods: An in vivo AD model was established in male KM mice via intraperitoneal injection of scopolamine. Cognitive function was assessed using the Morris water maze, and hippocampal levels of acetylcholine (ACh), acetylcholinesterase (AChE), glutathione peroxidase (GSH-Px), and reactive oxygen species (ROS) were measured using ELISA. In vitro, PC12 cells were exposed to Aβ25-35 to induce apoptosis. Immunofluorescence staining, Western blotting, and qPCR were used to assess the expression of amyloid-beta (Aβ), apoptosis-related protein caspase-3, and inflammatory cytokines (TNF-α, IL-1β). Active components of KSG and their potential targets and pathways were identified using mass spectrometry and network pharmacology, while partial validation was performed using molecular docking and Western blotting.Results: In vivo, KSG significantly alleviated scopolamine-induced cognitive deficits in mice. Treatment increased hippocampal levels of ACh and GSH-Px while reducing AChE and ROS. In vitro, KSG mitigated Aβ25-35-induced cytotoxicity in PC12 cells, decreased Aβ accumulation, and downregulated the expression of TNF-α and IL-1β. However, KSG had no significant effect on telomerase activity, telomere length, or the expression of the telomere-associated protein POT1. Mass spectrometry and network pharmacology analyses identified genistein, quercetin, and apigenin as key active compounds with TP53, AKT1, PTGS2, and CNR2 identified as core targets. Molecular docking validation confirmed the favorable binding activity between them. The calcium signaling, PI3K-Akt, and MAPK pathways emerged as the primary enriched pathways.Conclusion: KSG improves cognitive function and attenuates Aβ-induced neuronal damage in AD through multi-component, multi-target synergistic mechanisms. These effects appear to be mediated by modulation of the cholinergic system, inhibition of oxidative stress and inflammation, and suppression of neuronal apoptosis. These findings provide a theoretical basis and experimental support for developing novel AD therapies based on traditional Chinese medicine.

14 October 2023 in Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
SZSi-Shuo Zhang
Si-Shuo Zhang
JZJi-Wei Zhang
Ji-Wei Zhang
KZKai-Xin Zhang
Kai-Xin Zhang
WCWen-Qiang Cui
Wen-Qiang Cui
HZHongwei Zhi
Hongwei Zhi
YWYa-Han Wang
Ya-Han Wang

1 September 2025 in International Journal of General Medicine
Verified
Journal Article
Open access
PDF file
CXChao Xin
Chao Xin
HZHong-Wei Zhi
Hong-Wei Zhi
DWDa-Hua Wu
Da-Hua Wu
PDPeng-Li Ding
Peng-Li Ding
ZWZhong-Lin Wang
Zhong-Lin Wang
YWYa-Han Wang
Ya-Han Wang
Introduction: Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by gene expression alterations and immune dysregulation. Methods: In this study, we downloaded the GSE181279 single-cell dataset from the Gene Expression Omnibus (GEO) and applied bioinformatic analysis and clinical subject validation. Results: After quality control and harmony integration, we identified 21 cell subsets, including T cells, B cells, plasma cells, and macrophages. Plasma cells were significantly elevated in AD patients, and six plasma cell subtypes were associated with AD. High-dimensional weighted gene co-expression network analysis (hdWGCNA) revealed two AD-related modules. Mendelian randomization identified RGS1 as a key risk gene (p = 0.0123). Immune infiltration analysis showed RGS1 negatively correlated with macrophages and positively with tumor-infiltrating lymphocytes. Functional enrichment indicated that RGS1 is involved in JAK-STAT, NF-κB, and Wnt-β-catenin signaling pathways, suggesting a role in immune regulation and neuroinflammation. Furthermore, validation in AD patients confirmed that RGS1 expression levels were higher than in controls (p < 0.01). Discussion: This study identified the key gene RGS1 related to AD and explored multiple signaling pathways associated with it, which provided important clues for the research on AD-related inflammation, gut microbiota, stretch-gated ion channel, and the evaluation of AD therapeutic targets. Clinical Trial Registration Number: CTR20210477.